[Tofacitinib].
Tofacitinib is the first Janus kinase inhibitor which was approved for the therapy of rheumatoid arthritis in the USA. Several phase III studies proved the efficacy of Tofacitinib as monotherapy or in combination with established medication. This article discusses the therapeutic potential of this new pharmacological approach and the current data on efficacy and safety of Tofacitinib therapy with special emphasis on a prospective approval in the EU.